Evaluation of mediVR-KAGURA Guided Therapy

Sponsor
Japan Society of Clinical Research (Other)
Overall Status
Completed
CT.gov ID
NCT04562662
Collaborator
(none)
20
1
1
18.9
1.1

Study Details

Study Description

Brief Summary

The objective is to evaluate mediVR-KAGURA guided therapy for the treatments of physical and cognitive dysfunctions regardless of baseline disease in a prospective interventional design.

Condition or Disease Intervention/Treatment Phase
  • Device: mediVR KAGURA
N/A

Detailed Description

The patients sit on an upright chair, wear a head-mounted display (HMD) and grab two handheld controllers in a motion-tracked three-dimensional space called "room scale" of the mediVR-KAGURA (mediVR, Inc. Toyonaka City, Osaka, Japan). mediVR-KAGURA can provide users with >90 frames per second (fps) graphic operation with an approximately 110° viewing angle and accurate three-dimensional tracking technology.

First, we evaluate conventional and maximum reaching distances at 0°, 45°, and 90° level surface for the left hand (0L, 45L, 90L) and at 90°, 135°, and 180° level surface for the right hand (90R, 135R, or 180R) for calibration in a sitting position. During rehabilitation, patients are instructed to touch a fixed objects or catch a falling objects at the pre-specified height and distance levels in each degree. Horizontal distances were classified into three categories, namely long, middle, and short which were calculated using the following formulas: 0.9 * maximum reaching distance, 0.9 * (conventional + maximum reaching distances)/2, and conventional reaching distance respectively. A falling object disappeared at a 20 cm height for safety if the patients missed to catch it. The purpose of reaching hands was to stimulate and break down body trunk balance, and to train participants to balance for stable walking. By thinking about the timing and distance and recognizing the next targets repeatedly, cognitive function was simultaneously stimulated for dual-task training.

The 7 parameters of the rehabilitation programs can be set like as follows: (1) distance (short, middle or long), (2) direction (0L, 45L, 90L, 90R, 135R, or 180R), (3) height of object, (4) size of object (center or outline), (5) size of sensing sphere of the controller, (6) falling speed of the square box (from 0 to 300 cm/s), and (7) intervals for each task. Participants first underwent practical programs to familiarize themselves with mediVR-KAGURA guided rehabilitation, followed by rehabilitation programs. Provision of the rehabilitation programs will be personalized.

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of mediVR-KAGURA Guided Therapy: A Prospective Interventional Study
Actual Study Start Date :
Sep 1, 2020
Actual Primary Completion Date :
Mar 31, 2022
Actual Study Completion Date :
Mar 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention group

Single arm (all participants receive interventions)

Device: mediVR KAGURA
Approximately 20 min mediVR KAGURA-guided rehabilitation

Outcome Measures

Primary Outcome Measures

  1. Change in Timed up and go test [baseline (pre-intervention), immediately after the first intervention, average of 1, 3 and 6 months after the intervention]

    The Timed Up and Go test (TUG) is a simple test used to assess a person's mobility and requires both static and dynamic balance. Shorter score means a better outcome. The minimum value could be 5 seconds or less, and the maximum value could be infinity (cannot complete the test).

  2. Change in Trail Making Test [baseline (pre-intervention), immediately after the first intervention, average of 1, 3 and 6 months after the intervention]

    The Trail Making Test (TMT) is a neuropsychological test of visual attention and task switching. Shorter score means a better outcome. The minimum value could be 15 seconds or less, and the maximum value could be infinity or be defined as 300 seconds when patients cannot complete the test.

Secondary Outcome Measures

  1. Changes in Functional Independence Measure [baseline (pre-intervention), immediately after the first intervention, average of 1, 3 and 6 months after the intervention]

    The Functional Independence Measure (FIM) is an assessment tool that aims to evaluate the functional status of patients throughout the rehabilitation process following a stroke, traumatic brain injury, spinal cord injury or cancer. Higher score means a better outcome. The minimum value is 18, and the maximum value is 126.

  2. Changes in Berg balance scale [baseline (pre-intervention), immediately after the first intervention, average of 1, 3 and 6 months after the intervention]

    The Berg Balance Scale (or BBS) is a widely used clinical test of a person's static and dynamic balance abilities. Higher score means a better outcome. The minimum value is 0, and the maximum value is 56.

  3. Changes in Mini Mental State Examination [baseline (pre-intervention), immediately after the first intervention, average of 1, 3 and 6 months after the intervention]

    The Mini-Mental State Examination (MMSE) test is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment. Higher score means a better outcome. The minimum value is 0, and the maximum value is 30.

  4. Changes in Self Rating Depression Scale [baseline (pre-intervention), immediately after the first intervention, average of 1, 3 and 6 months after the intervention]

    The Self Rating Depression Scale (SDS) is a psychiatric measuring instrument having descriptive words and phrases that indicate the severity of depression for a time period. Lower score means a better outcome. The minimum value is 20, and the maximum value is 80.

Eligibility Criteria

Criteria

Ages Eligible for Study:
6 Years to 110 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Patients with physical and/or cognitive dysfunctions

  2. Agreed to the participation of this study with written informed consent by themselves or guardians

Exclusion Criteria:
  1. Inappropriate candidates at attending physician's discretion

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cloud Clinic Takarazuka Hyogo Japan 6650066

Sponsors and Collaborators

  • Japan Society of Clinical Research

Investigators

  • Study Chair: Masahiko Hara, MD, PhD, Cloud Clinic

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Masahiko Hara, Principal Investigator, Japan Society of Clinical Research
ClinicalTrials.gov Identifier:
NCT04562662
Other Study ID Numbers:
  • 202001
First Posted:
Sep 24, 2020
Last Update Posted:
Aug 16, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Masahiko Hara, Principal Investigator, Japan Society of Clinical Research
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2022